Literature DB >> 12781921

Modification of cardiovascular response of posterior hypothalamic adenosine A(2) receptor stimulation by adenylate cylase, guanylate cyclase and by K(ATP) channel blockade in anesthetized rats.

Min Jeong Kang1, Moon Seung Park, In Chul Shin, Hyun Chul Koh.   

Abstract

Cardiovascular inhibitory effects induced by posterior hypothalamic adenosine A(2) receptors and their modulation by nitric oxide were suggested by our previous report. In this experiment, we examined the modulation of cardiovascular effects of adenosine A(2) receptor stimulation by adenylate cyclase, guanylate cyclase and ATP-sensitive K(+) channel in the posterior hypothalamus. Posterior hypothalamic injection of drugs was performed in anesthetized, artificially ventilated male Sprague-Dawley rats. Injection of adenosine A(2) receptor agonist 5'-(N-cyclopropyl)-carboxamidoadenosine (CPCA; 1, 2 and 5 nmol) produced a dose-dependent decrease of blood pressure and heart rate. Pretreatment with adenosine A(2) receptor antagonist 3,7-dimethyl-1-propargylxanthine (10 nmol) blocked the depressor and bradycardiac effects of CPCA (5 nmol). Pretreatments with adenylate cyclase inhibitor MDL-12330 (10 nmol) and guanylate cyclase inhibitor LY-83583 (5 nmol) attenuated the depressor and bradycardiac effects of CPCA (5 nmol). In addition, pretreatment with ATP-sensitive K(+) channel blocker glipizide (20 nmol) attenuated the depressor and bradycardiac responses of CPCA (5 nmol). These results suggest that posterior hypothalamic adenosine A(2) receptors play an inhibitory role in the central cardiovascular regulation and that both adenylate cyclase and guanylate cyclase mediate the depressor and bradycardiac actions of adenosine A(2) receptors. Also, ATP-sensitive K(+) channel mediates the posterior hypothalamic cardiovascular regulations of adenosine A(2) receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781921     DOI: 10.1016/s0304-3940(03)00402-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Adverse effects associated with regadenoson myocardial perfusion imaging.

Authors:  Efstathia Andrikopoulou; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2018-02-21       Impact factor: 5.952

2.  Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.

Authors:  Efstathia Andrikopoulou; Charity J Morgan; Lizbeth Brice; Navkaranbir S Bajaj; Harish Doppalapudi; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-10-17       Impact factor: 5.952

3.  Asystole following regadenoson infusion in stable outpatients.

Authors:  Jeffrey Rosenblatt; Deirdre Mooney; Timothy Dunn; Mylan Cohen
Journal:  J Nucl Cardiol       Date:  2014-05-31       Impact factor: 5.952

4.  Vasodepressor Effects of Adenosine in the Cat are Independent of Cyclooxygenase, Potassium Channels, and Nitric Oxide Pathways.

Authors:  Alan David Kaye; Syed R Baber; Mohammed T Sharief; Rachel J Kaye; Elyse M Cornett
Journal:  Drugs R D       Date:  2019-12

5.  Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy.

Authors:  M Brinkert; E Reyes; S Walker; K Latus; A Maenhout; R Mizumoto; C Nkomo; K Standbridge; K Wechalekar; S R Underwood
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-22       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.